NCODA Logo

The development and utilization of oral oncolytics has steadily increased over the past 20 years. There are over 800 new oncology therapies in the drug development pipeline, 25%-35% of which are oral agents.1 The use of oral oncolytics presents unique challenges to patient safety compared to intravenous cancer treatments. As oral oncolytics are self-administered, it is important for the patient and caregiver to understand the appropriate dosing, frequency, duration of therapy, storage, and safe handling recommendations. Additionally, it is important for providers to explain the risks and benefits of the proposed therapy specific to each oral medication and to have an evidence-based plan for managing each patient on oral oncolytic therapy.

Download the Full Care Plan HERE